Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randi Hagerman

Showing results (141-150 of 159) with videos related to

Pageof 16
Sort By:
Journal of Medical Genetics|July 1, 2021
Hypermobile Ehlers-Danlos syndrome (hEDS) phenotype in fragile X premutation carriers: case seriesNattaporn Tassanakijpanich, Forrest J McKenzie, Yingratana A McLennan, et al.
Journal of Neurodevelopmental Disorders|August 7, 2014
Associated features in females with an FMR1 premutationAnne C Wheeler, Donald B Bailey, Elizabeth Berry-Kravis, et al.
Journal of Neurodevelopmental Disorders|November 19, 2025
Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension studyElizabeth Berry-Kravis, Randi Hagerman, Jonathan Cohen, et al.
Science Signaling|June 9, 2016
Augmented noncanonical BMP type II receptor signaling mediates the synaptic abnormality of fragile X syndromeRisa Kashima, Sougata Roy, Manuel Ascano, et al.
Pediatrics|November 7, 2012
Newborn, carrier, and early childhood screening recommendations for fragile XLiane Abrams, Amy Cronister, William T Brown, et al.
Cerebellum (London, England)|June 12, 2016
Update on the Clinical, Radiographic, and Neurobehavioral Manifestations in FXTAS and FMR1 Premutation CarriersDeborah A Hall, Erin Robertson, Annie L Shelton, et al.
Journal of Child and Adolescent Psychopharmacology|October 31, 2006
Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trialElizabeth Berry-Kravis, Sue Ellen Krause, Sandra S Block, et al.
International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience|September 19, 2023
Adaptive, behavioral, and cognitive outcomes in individuals with fragile X syndrome with varying autism severityRamkumar Aishworiya, Ye Eun Tak, Matthew Dominic Ponzini, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 30, 2006
Progression of tremor and ataxia in male carriers of the FMR1 premutationMaureen A Leehey, Elizabeth Berry-Kravis, Sung-Joon Min, et al.
Frontiers in Molecular Neuroscience|June 22, 2026
Glymphatic dysfunction and neuroinflammation in FXTAS: evidence from DTI-ALPS and gene expression analysisAndrea Elias-Mas, Esther Granell Moreno, Cèlia Painous Martí, et al.
Pageof 16

Showing results (141-150 of 159) with videos related to

Sort By:
Pageof 16
Journal of Medical Genetics|July 1, 2021
Hypermobile Ehlers-Danlos syndrome (hEDS) phenotype in fragile X premutation carriers: case seriesNattaporn Tassanakijpanich, Forrest J McKenzie, Yingratana A McLennan, et al.
Journal of Neurodevelopmental Disorders|August 7, 2014
Associated features in females with an FMR1 premutationAnne C Wheeler, Donald B Bailey, Elizabeth Berry-Kravis, et al.
Journal of Neurodevelopmental Disorders|November 19, 2025
Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension studyElizabeth Berry-Kravis, Randi Hagerman, Jonathan Cohen, et al.
Science Signaling|June 9, 2016
Augmented noncanonical BMP type II receptor signaling mediates the synaptic abnormality of fragile X syndromeRisa Kashima, Sougata Roy, Manuel Ascano, et al.
Pediatrics|November 7, 2012
Newborn, carrier, and early childhood screening recommendations for fragile XLiane Abrams, Amy Cronister, William T Brown, et al.
Cerebellum (London, England)|June 12, 2016
Update on the Clinical, Radiographic, and Neurobehavioral Manifestations in FXTAS and FMR1 Premutation CarriersDeborah A Hall, Erin Robertson, Annie L Shelton, et al.
Journal of Child and Adolescent Psychopharmacology|October 31, 2006
Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trialElizabeth Berry-Kravis, Sue Ellen Krause, Sandra S Block, et al.
International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience|September 19, 2023
Adaptive, behavioral, and cognitive outcomes in individuals with fragile X syndrome with varying autism severityRamkumar Aishworiya, Ye Eun Tak, Matthew Dominic Ponzini, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 30, 2006
Progression of tremor and ataxia in male carriers of the FMR1 premutationMaureen A Leehey, Elizabeth Berry-Kravis, Sung-Joon Min, et al.
Frontiers in Molecular Neuroscience|June 22, 2026
Glymphatic dysfunction and neuroinflammation in FXTAS: evidence from DTI-ALPS and gene expression analysisAndrea Elias-Mas, Esther Granell Moreno, Cèlia Painous Martí, et al.
Pageof 16